The Medicare Bridge Program launched July 1, 2026 and gives eligible Medicare Part D enrollees access to FDA-approved GLP-1 weight-loss drugs — Wegovy, Zepbound, and the new oral Foundayo — for a flat $50 per month copay. If you have Medicare and a qualifying BMI, your monthly bill for brand-name GLP-1 therapy just dropped from $399–$1,600 to a single $50 copay.
By Alexandru Vieru | Independently researched | Published August 2026. Coverage data verified: July 2026.
Quick answer: The Medicare bridge program runs from July 1, 2026 through December 31, 2027. Eligible enrollees need Medicare Part D drug coverage and either a BMI of 35 or higher, or a BMI of 27 or higher with a qualifying condition such as cardiovascular disease, prediabetes, or hypertension. The catch: the $50 copay does not count toward your Part D deductible or your annual out-of-pocket limit, and coverage ends December 31, 2027. For the full picture on GLP-1 costs, see our GLP-1 weight loss cost guide for 2026.
What Is the Medicare Bridge Program?
The Medicare bridge program is a temporary drug-coverage initiative under the CMS Innovation Center's BALANCE Model (Broad Access to Lower-Cost GLP-1 Coverage for Eligible Needs). It was authorized by CMS and took effect July 1, 2026.
Before July 2026, Medicare Part D covered Wegovy only for patients with established cardiovascular disease — not for weight loss alone. Zepbound had no Medicare coverage at all. The bridge program changes that by creating a separate payment track: a flat $50 per-month copay for qualifying Part D plan members who need GLP-1 therapy for obesity or overweight with a comorbidity, regardless of whether their plan formulary previously covered these drugs for weight management.
The program does not permanently rewrite Medicare drug law. The statutory exclusion on weight-loss medications (Section 1860D-2(e)(2)(A) of the Social Security Act) remains in place. The medicare bridge program operates as a demonstration model alongside existing Part D coverage rules, with a defined 18-month window.
Why it matters: Before this program, a Medicare beneficiary wanting Wegovy for weight loss was looking at $899 or more per month out-of-pocket, or a cash-pay compounded semaglutide plan at $133–$299 per month. The medicare bridge program lowers the branded-drug door to $50 per month for those who qualify — a fundamental shift in affordability for older Americans.
According to Medicare's official fact sheet on the bridge program, the $50 copay applies uniformly: it doesn't vary by plan, drug tier, or Medicare health plan type.
Which Drugs Does the Medicare Bridge Program Cover?
The Medicare bridge program covers three FDA-approved GLP-1 medications as of July 2026:
| Drug | Form | Included in Bridge? |
|---|---|---|
| Wegovy (semaglutide) | Weekly injection OR oral tablet | ✅ Yes |
| Foundayo (oral GLP-1 tablet) | Daily or weekly oral tablet | ✅ Yes |
| Zepbound (tirzepatide) | KwikPen only | ✅ Yes |
| Zepbound single-dose pen | Injection | ❌ Not included |
| Zepbound vials | Injection | ❌ Not included |
| Compounded semaglutide / tirzepatide | Any form | ❌ Not included |
| Rybelsus | Daily oral tablet | ❌ Not a weight-loss indication |
A few details that matter in practice:
Wegovy (injection and oral): Both formulations — the classic weekly injection pen and the newer oral semaglutide tablet — are included. This is the most widely prescribed drug in the bridge program.
Foundayo: This is an oral GLP-1 tablet FDA-approved for chronic weight management. It is covered under the bridge program and offers a needle-free option for patients who prefer not to inject.
Zepbound (KwikPen only): Critically, only the KwikPen presentation of tirzepatide is covered. The single-dose vials and single-dose pens that Eli Lilly sells through its LillyDirect cash program are excluded. If your prescriber writes for vials, your pharmacist must switch to the KwikPen or the $50 copay does not apply.
Compounded GLP-1 is not included. The Medicare bridge program covers only FDA-approved brand-name medications dispensed through licensed pharmacies. Compounded semaglutide and compounded tirzepatide from 503A pharmacies do not qualify. For the legal status of compounded options and what they cost, see is compounded GLP-1 still legal in 2026?.
Medicare Bridge Program Eligibility: Who Qualifies?
The Medicare bridge program has four requirements. All four must be met simultaneously:
1. Medicare Part D drug coverage. You must be enrolled in a standalone Medicare Prescription Drug Plan (PDP) or a Medicare Advantage plan with prescription drug coverage (MAPD). Original Medicare alone (Parts A and B only) does not qualify.
2. BMI of 35 or higher. OR —
3. BMI of 27 or higher with at least one qualifying comorbidity:
- Established cardiovascular disease
- Type 2 diabetes or prediabetes
- Hypertension (high blood pressure)
- Obstructive sleep apnea
- Certain other obesity-related conditions
4. A valid prescription from a licensed U.S. prescriber for one of the covered medications (Wegovy, Foundayo, or Zepbound KwikPen) specifically for chronic weight management.
| Eligibility requirement | Passes? |
|---|---|
| Medicare Part D coverage | Must be enrolled |
| BMI ≥ 35 OR BMI ≥ 27 + qualifying condition | At least one must apply |
| Prescription for Wegovy / Foundayo / Zepbound KwikPen | Required |
| Drug used for weight management (not other indication) | Must match |
Who is excluded: Medicare Advantage members whose plans have placed Wegovy or Zepbound on a restricted formulary tier are still eligible — the bridge program overrides plan-level tier placement for the $50 copay. However, if a plan requires step therapy (proving failure of diet/exercise programs first), that step-therapy requirement still applies. The bridge program controls the price; it does not eliminate prior authorization or step-therapy protocols.
Medicare beneficiaries who want tirzepatide but whose prescribers write for vials (not the KwikPen) are currently excluded. Patients in this situation should ask their prescriber to update the prescription to specify the KwikPen formulation.
The $50 Copay: What It Covers — and What It Doesn't
The Medicare bridge program flat copay is $50 per month. But the program has a significant structural limitation you need to understand before enrolling.
The $50 copay does not count toward your Part D deductible — the annual amount you pay before Part D coverage kicks in (up to $590 in 2026).
The $50 copay does not count toward your $2,100 annual Part D out-of-pocket (OOP) limit. In standard Part D, every dollar you spend on covered medications counts toward this cap; once you hit $2,100, your cost is $0 for the rest of the year. Bridge program copays are excluded from this calculation.
In practice, this means:
- You pay $50 per month, every month of the program, with no OOP ceiling benefit
- A full year of coverage under the bridge costs $600 (12 × $50)
- These payments do not accelerate you toward catastrophic coverage
For most Medicare beneficiaries, $50/month is still a dramatic improvement over the $899+/month cash-pay reality. But patients with multiple expensive medications who are tracking toward their annual OOP limit may see a modest disadvantage compared to if bridge payments counted toward that cap.
The program also does not guarantee long-term access. The Medicare bridge program ends December 31, 2027. CMS has not committed to extending it, and Congress has not yet passed legislation making permanent coverage for anti-obesity medications under Medicare a statutory right. Patients who start on brand-name GLP-1 therapy through the bridge program should discuss a continuity plan with their prescriber before the program ends.
How to Get Wegovy or Zepbound Under the Medicare Bridge Program
The Medicare bridge program is accessed through your existing Part D plan — you do not need to switch plans or enroll separately. Here is the process:
-
Confirm your Part D eligibility. Check your Medicare card or your plan's member portal to confirm you have Part D coverage. If you only have Parts A and B, you need to enroll in a Part D plan during an eligible enrollment period.
-
Get a prescription. Ask your primary care physician, internist, or a telehealth provider to prescribe Wegovy, Foundayo, or Zepbound (KwikPen specifically) for chronic weight management. Your BMI must meet the threshold and be documented in your chart.
-
Fill the prescription at a participating pharmacy. Most large retail and mail-order pharmacies (CVS, Walgreens, Rite Aid, Express Scripts, OptumRx) participate in the bridge program. The $50 copay applies at the point of sale. If your pharmacy quotes a higher price, confirm with them that they have applied the bridge program pricing.
-
Expect prior authorization. Your plan may still require prior authorization documenting your BMI, qualifying condition (if BMI is 27–34), and clinical necessity. This is the most common delay point — your prescriber's office typically handles the PA submission.
-
Choose the right Zepbound formulation. If you are prescribed tirzepatide, confirm the KwikPen formulation is specified on the prescription. Vials are not covered by the bridge program.
Does the Medicare Bridge Program Replace Compounded GLP-1?
For Medicare beneficiaries, the Medicare bridge program makes brand-name drugs far more affordable than compounded alternatives for the first time. But the comparison is not one-size-fits-all.
When the Medicare bridge program is the better choice:
- You already have Medicare Part D and a qualifying BMI
- You want FDA-approved brand-name Wegovy or Zepbound with full regulatory oversight
- You prefer the guaranteed $50/month price point over the slightly lower cash cost of compounded GLP-1
When compounded GLP-1 may still make sense (for Medicare patients):
- Your plan denies prior authorization and you cannot navigate the appeals process
- You want tirzepatide in vial form (which the bridge does not cover) and your prescriber prefers that formulation
- You are seeking a multi-compound formula (e.g., semaglutide with B12 or carnitine) not available in brand form
From a cost perspective: compounded semaglutide starts at $133/month (Oak) and compounded tirzepatide at $199–$279/month, while the Medicare bridge program offers brand-name drugs at $50/month. For eligible Medicare patients, the bridge program is almost always the better financial choice. The catch is that compounded programs typically have less paperwork — no prior authorization, no BMI documentation requirements, no formulary battles.
If you are not on Medicare or you are under 65, this program does not apply to you. For the most affordable compounded GLP-1 options for cash-pay patients, see our cheapest GLP-1 online guide and our comparison of brand vs. compounded semaglutide in 2026.
Medicare Bridge Program vs. Cash-Pay Compounded GLP-1: Side-by-Side
| Factor | Medicare Bridge Program | Compounded GLP-1 (Cash-Pay) |
|---|---|---|
| Monthly cost | $50/month (flat) | $133–$299/month |
| Who is eligible | Medicare Part D enrollees | Anyone (no insurance required) |
| Drug type | FDA-approved brand (Wegovy, Foundayo, Zepbound) | Compounded 503A pharmacy (not FDA-approved) |
| Prior authorization | Usually required | Not required |
| Program duration | Through Dec 31, 2027 | Ongoing (pending 503B rule) |
| Copay counts toward OOP | No | N/A (cash) |
| Telehealth access | Most plans, some telehealth | All major telehealth clinics |
| Best for | Medicare Part D enrollees, BMI threshold met | Under 65, uninsured, or failed PA |
For Medicare patients who qualify, the bridge program wins on cost by a wide margin. For the roughly 85% of GLP-1 seekers who are under 65 and paying cash, the compounded market remains the primary access point. Clinics like Wellorithm (which offers both brand-name Wegovy and compounded options from $147/month) and Gala Health (best overall rated at 8.3/10, from $149/month) are the leading options for non-Medicare patients.
What If You're Under 65 or Don't Have Medicare?
The Medicare bridge program is not available to you if you do not have Medicare. For the majority of GLP-1 weight-loss patients — those under 65, on employer insurance, or uninsured — the landscape has not changed:
-
With commercial insurance: Most large employer plans (UHC, Aetna, Cigna, BCBS) cover Wegovy or Zepbound with prior authorization. Coverage expanded in 2024–2025 but a significant portion of employer plans have also restricted or dropped GLP-1 coverage. See our Zepbound insurance coverage guide for the current picture.
-
Without insurance (cash-pay): Compounded semaglutide from a licensed 503A telehealth clinic remains the most affordable legal option at $133–$299/month. The 503B ban proposed by FDA in April 2026 affects only large outsourcing facilities — 503A compounding by individual pharmacies for specific patients remains legal with proper prescriptions. For our ranked picks: compare GLP-1 clinics.
-
For telehealth access to brand-name GLP-1: Only a handful of clinics offer brand-name Wegovy or Zepbound alongside compounded options. Wellorithm is currently the only provider in our ranking that carries brand-name Wegovy, Mounjaro, Ozempic, and Zepbound alongside compounded GLP-1 from $147/month.
What Happens After the Medicare Bridge Program Ends in 2027?
The Medicare bridge program is authorized through December 31, 2027. CMS has framed it as a demonstration to collect data on GLP-1 outcomes and costs in Medicare before making permanent coverage decisions.
Three scenarios are plausible after 2027:
-
Congress passes permanent GLP-1 coverage for Medicare. Legislation expanding Medicare drug coverage for anti-obesity medications has been introduced multiple times. If the bridge program data shows strong outcomes and reasonable cost, political support could accelerate permanent coverage.
-
CMS extends the model. CMMI has authority to extend successful demonstrations. A year-over-year extension is possible without congressional action.
-
Coverage ends January 1, 2028. Patients who started on branded GLP-1 therapy under the bridge program would return to the pre-July 2026 status quo: Wegovy only under CVD indication, Zepbound not covered. Planning for this scenario means discussing with your prescriber whether continued access via cash-pay, commercial supplement coverage, or a compounded alternative would be viable.
Medicare beneficiaries currently on compounded GLP-1 should take note: if you qualify for the bridge program, switching to brand-name at $50/month makes sense now. But the decision should account for the 2027 cliff. A prescriber conversation about your long-term plan is warranted before switching.
Frequently Asked Questions
Does the Medicare bridge program cover Ozempic? No. Ozempic is FDA-approved for type 2 diabetes, not for weight loss. The bridge program covers Wegovy (the weight-loss formulation of semaglutide), Foundayo, and Zepbound (KwikPen). Ozempic prescribed off-label for weight loss is not covered under this program.
Do Medicare Advantage plans participate in the bridge program? Yes. Both standalone Part D (PDP) plans and Medicare Advantage plans with drug coverage (MAPD) participate. The flat $50 copay applies regardless of which plan you have, as long as you meet the BMI and eligibility requirements.
Will I need prior authorization for the Medicare bridge program? Most plans still require prior authorization documenting your BMI, qualifying condition, and the specific drug requested. The bridge program sets the price — it does not eliminate plan-level PA requirements. Your prescriber's office typically handles PA submission.
My doctor wrote for Zepbound vials. Does the bridge program cover that? No. The Medicare bridge program covers Zepbound in KwikPen form only. Single-dose vials and single-dose pens are excluded. Ask your prescriber to update the prescription to specify the KwikPen.
I'm on compounded semaglutide through a telehealth clinic. Should I switch? If you have Medicare Part D and meet the BMI threshold, the bridge program gives you brand-name Wegovy at $50/month — compared to $133–$299/month for compounded. For most Medicare patients, switching makes financial sense. Discuss with your prescriber to confirm eligibility and handle the PA paperwork.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded GLP-1 medications are not FDA-approved. Consult a licensed healthcare provider before starting, switching, or stopping any medication. Coverage data verified July 2026; check with your Medicare plan for current formulary and prior authorization requirements.
Affiliate disclosure: MyGLP1 Guides earns commissions from some clinic links. Commissions do not influence editorial scores or rankings. See our editorial policy.
Top Picks for Non-Medicare Patients
Not on Medicare? These are our top-rated GLP-1 clinics for cash-pay patients in 2026:
- Gala Health — Best Overall (8.3/10, from $149/mo): Compounded semaglutide + microdosing tiers, all 50 states.
- Wellorithm — Best for Brand + Compounded (8.3/10, from $147/mo): The only clinic in our ranking offering brand-name Wegovy, Mounjaro, Ozempic, and Zepbound alongside compounded options.
- Yucca Health — Best Value with Oversight (7.8/10, from $146/mo): LegitScript-certified, Trustpilot 4.6/5 from 1,000+ real reviews.
Related reading:
